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Atypical hemolytic uremic syndrome (aHUS) is a rare disease characterized by
microangiopathic hemolytic anemia, thrombocytopenia and renal failure. It is caused
by genetic or acquired defects of the complement alternative pathway. Factor H
autoantibodies (anti-FHs) have been reported in 10% of aHUS patients and are
associated with the deficiency of factor H-related 1 (FHR1). However, FHR1 deficiency
is not enough to cause aHUS, since it is also present in about 5% of Caucasian
healthy subjects. In this study we evaluated the prevalence of genetic variants in
CFH, CD46, CFI, CFB, C3, and THBD in aHUS patients with anti-FHs, using healthy
subjects with FHR1 deficiency, here defined “supercontrols,” as a reference group.
“Supercontrols” are more informative than general population because they share at
least one risk factor (FHR1 deficiency) with aHUS patients. We analyzed anti-FHs in
305 patients and 30 were positive. The large majority were children (median age: 7.7
[IQR, 6.6–9.9] years) and 83% lacked FHR1 (n = 25, cases) due to the homozygous
CFHR3-CFHR1 deletion (n = 20), or the compound heterozygous CFHR3-CFHR1 and
CFHR1-CFHR4 deletions (n= 4), or the heterozygousCFHR3-CFHR1 deletion combined
with a frameshift mutation in CFHR1 that generates a premature stop codon (n = 1).
Of the 960 healthy adult subjects 48 had the FHR1 deficiency (“supercontrols”). Rare
likely pathogenetic variants in CFH, THBD, and C3 were found in 24% of cases (n = 6)
compared to 2.1% of the “supercontrols” (P-value = 0.005). We also found that the CFH
H3 and the CD46GGAAC haplotypes are not associated with anti-FHs aHUS, whereas
these haplotypes are enriched in aHUS patients without anti-FHs, which highlights the
differences in the genetic basis of the two forms of the disease. Finally, we confirm
that common infections are environmental factors that contribute to the development
of anti-FHs aHUS in genetically predisposed individuals, which fits with the sharp peak
of incidence during scholar-age. Further studies are needed to fully elucidate the complex
genetic and environmental factors underlying anti-FHs aHUS and to establish whether the
combination of anti-FHs with likely pathogenetic variants or other risk factors influences
disease outcome and response to therapies.
Keywords: autoantibodies, atypical hemolytic uremic syndrome, factor H, factor H related 1, complement, genetic
variants, supercontrols
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INTRODUCTION
Atypical hemolytic uremic syndrome (aHUS) is a rare
disease characterized by microangiopathic hemolytic anemia,
thrombocytopenia and renal failure (1, 2). It is mainly caused
by genetic or acquired defects of the alternative pathway (AP)
of the complement system (3). Heterozygous likely pathogenic
variants (LPVs) in genes encoding complement regulators, such
as factor H (FH), factor I and CD46 (3–7), or components of
the AP C3 convertase (C3 and factor B) (3, 8–11) were found in
about half of aHUS patients. Moreover, genetic abnormalities in
thrombomodulin (THBD), an endothelial anticoagulant protein
that also regulates complement, were reported in 3–5% of aHUS
cases (12).
Incomplete penetrance was observed in carriers of genetic
abnormalities, indicating that although LPVs predispose to the
development of aHUS, additional genetic and/or environmental
hits are necessary for the disease to manifest (13). Indeed, in a
large multinational study, 25% of patients with LPVs in CD46
or CFI, and 8–10% of those with LPVs in CFH, C3, and CFB,
carried combined genetic abnormalities in other complement
genes (13). Common variants and haplotypes in CFH and CD46
have been associated with aHUS and were reported to increase
the penetrance of the disease in subjects carrying LPVs (14–16).
Factor H autoantibodies (anti-FHs) have been described in
about 10% of aHUS patients and are strongly associated with
the deficiency of factor H-related 1 (FHR1) (17–19). In most
cases, the lack of FHR1 is due to the polymorphic homozygous
deletion of the factor H related 3 and 1 genes (CFHR3-CFHR1)
(20). In about 15% of patients the FHR1 deficiency is caused
by compound heterozygous deletion of CFHR3-CFHR1 and
CFHR1-CFHR4, while homozygous CFHR1-CFHR4 deletion is
rare (21–23).
The pathogenic mechanism that links the FHR1 deficiency
with the risk of the development of anti-FHs has not been
clarified yet. Anti-FHsmainly target the C-terminal region of FH,
and also cross react with FHR1 short consensus repeats (SCRs)
4–5, which have very high amino acid sequence identity with
SCRs 19–20 of FH (24–27). It has recently been hypothesized
that binding of certain proteins expressed by pathogens to the
SCRs 19–20 of FH induces the exposure of a neoepitope in FH
that is conformationally similar to that in SCRs 4–5 of FHR1,
resulting in an autoimmune response in subjects with FHR1
deficiency (26).
Despite the above evidence, FHR1 deficiency is not enough
to cause anti-FH associated aHUS, which is an ultra-rare disease
with an estimated prevalence of 1:1,000,000 (1, 28). Indeed,
the CFHR3-CFHR1 deletion is a rather common polymorphism,
and is present in homozygosity in 3–10% of healthy European
populations and in 7–30% of African populations, whereas it is
very rare in Asia and South America (29). The combined CFHR3-
CFHR1 and CFHR1-CFHR4 deletion is present in 0.9% of healthy
European controls (22).
Autoimmune diseases are typically complex disorders in
which multiple susceptibility genetic variants and environmental
factors are involved (30, 31). The contribution of each genetic
variant is usually small and only the presence of multiple variants
favors the development of the disease (31). Notably, each single
risk variant may be found in healthy subjects, although at a lower
frequency than in patients, but it is the combination of multiple
risk variants that clusters with the disease (30).
Previous studies reported that about 14.7% of aHUS patients
with anti-FHs also carry LPVs in complement genes (18, 19, 21–
23, 32); however the prevalence of LPVs in patients with anti-
FHs should be compared to that in the general population or,
even better, in a control group with FHR1 deficiency. This would
support the hypothesis that LPVs have a role in anti-FHs aHUS.
In this study we investigated the genetic determinants of anti-
FH-associated aHUS by comparing patients with anti-FHs and
FHR1 deficiency (defined here as “cases”) and adult healthy
subjects carrying the homozygous CFHR1 deletion (defined here
as “supercontrols”) as a homogeneous, special control group,
to optimize the power to detect differences. We hypothesized
that the “supercontrols” were depleted for risk variants or
even enriched in protective variants, since they evaded the
development of aHUS despite carrying the known risk factor
represented by the FHR1 deficiency.
Specifically, we compared the prevalence of rare LPVs in
complement genes between cases and “supercontrols.” We also
investigated the association with anti-FHs aHUS of common
variants in complement genes, which in previous studies were
reported to increase the risk of aHUS or of other immune-
mediated glomerulopathies (33–38).
We found that rare LPVs but not common complement gene
variants are enriched to a significant extent in cases compared to
“supercontrols,” suggesting they are involved in the development
of anti-FHs aHUS.
METHODS
Patients and Controls
In all patients, atypical HUS was diagnosed based on
microangiopathic hemolytic anemia and thrombocytopenia
defined as hematocrit <30%, hemoglobin level <10 g/dl,
serum lactate dehydrogenase level above 500 U/l, undetectable
haptoglobin level, fragmented erythrocytes in peripheral blood
smear, and platelets below 150 × 103/µl, associated with acute
renal failure (serum creatinine >1.3 mg/dl for adults, >0.5
mg/dl for children under 5 years of age and >0.8 mg/dl for
children aged 5–10 years old; and/or urinary protein/creatinine
ratio >200 mg/g; or an increase of serum creatinine or urinary
protein/creatinine ratio >15% compared to baseline levels).
All aHUS patients (n = 305) were recruited through the
International Registry of HUS/TTP (Ranica, Bergamo, Italy).
Healthy adult subjects (n = 960) were from internal donors
and from the Piedmont Regional Registry of the Italian Bone
Marrow Donors Registry (Azienda Ospedaliera–Universitaria,
Città della Salute e della Scienza, Turin, Italy). Patient and healthy
subject data were handled with respect for confidentiality and
anonymity. All subjects provided informed written consent in
accordance with the Declaration of Helsinki. The study was
approved by the Ethics Committee of Azienda Sanitaria Locale,
Bergamo, Italy.
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Anti-FH IgG ELISA
The presence of anti-FH IgGs was evaluated through an Enzyme-
Linked Immunosorbent Assay (ELISA). Microtiter plates were
coated with 100 µl of a solution of 1µg/ml of purified
human FH (0.1 µg, Calbiochem). After overnight incubation
at 4◦C, the plate was washed with Phosphate-Buffered Saline
(PBS), 0.1% Tween20, and 0.2M NaCl and blocked with PBS,
0.1% Tween 20, and 0.3% milk powder. After washes, 50
µl of plasma/serum samples at 1:100 dilution were added to
duplicated wells, and incubated for 40min. A parallel plate was
set up in the absence of FH coating, in which only blocking
solution was added to evaluate the presence of non-FH specific
background, according to published recommendations (39).
After washes, goat anti-human IgG antibody conjugated with
horseradish peroxidase (HRP, 1:250, Sigma-Aldrich) was added
and incubated for 1 h. Enzymatic activity was revealed using
the 3,3′,5,5′-tetramethylbenzidine (TMB) substrate. A positive
control kindly gifted by Dr. Marie-Agnes Dragon-Durey, with
2,000 AU/ml titer was used at 1:100 dilution. The positive
threshold was set up at the mean titer +2 standard deviations
(SD) found in plasma samples of 98 healthy controls with 1
or 2 copies of CFHR1 (56 AU/ml). The sample concentrations
expressed in arbitrary units/ml (AU/ml) were extrapolated from a
sigmoidal curve and the background derived from wells without
FH coating was subtracted. The ELISA was repeated in positive
samples, adding 15 µg of FH into each sample to verify antibody
specificity. Samples showing at least a 50% decrease of the ELISA
absorbance in the assay performed in the presence of exogenous
FH were considered as true positive.
This ELISA protocol was also used to evaluate the binding of
autoantibodies to SCRs 1–5 and 15–20 FH fragments obtained
by baculovirus transfection of Spodoptera frugiperda cells as
reported (40). The plate was coated with molar equivalents of FH
SCRs 1–5 and 15–20 and the results were expressed as absorbance
at 450 nm. In a selected experiment, additional wells were coated
with full length FH (positive control) or bovine serum albumin
(BSA, negative control).
HMEC-1
Serum-induced C5b-9 deposition on a human microvascular
endothelial cell line (HMEC-1) was analyzed as previously
described, with minor modifications (41). HMEC-1 were plated
on glass coverslips and used when confluent. Cells were activated
with 10µM ADP for 10min and incubated for 4 h with serum
from patients (ID: 18 and 20) or healthy controls diluted 1:2 with
test medium (Hank’s Balanced Salt Solution—HBSS+0.5% BSA).
HMEC-1 were fixed and stained with rabbit anti-human C5b-
9 antibody, followed by FITC-conjugated antibody. Fluorescent
staining on cell surface was acquired in 15 fields through confocal
microscopy and the staining area was evaluated using Image J
software. Results were expressed as the percentage of staining
in relation to a pooled control sera (n = 10 subjects) run in
parallel. The sera from additional 35 controls were analyzed
separately and the percentages of C5b-9 deposits vs. control
serum pool were calculated to establish the normal range (mean
± 2SD of % C5b-9 deposits of the control sera vs. control serum
pool: 60–149%).
FH ELISA
FH levels were evaluated by ELISA. Microtiter plates were
coated with 0.15 µg of purified sheep polyclonal anti-human
factor H antibody (Abcam). After three washes with PBS, 0.05%
Tween20, the plate was blocked with 200 µl of PBS, 1% BSA.
After four washes with PBS, 0.05% Tween20, 100 µl of plasma
samples at 1:10,000 dilution were added to duplicated wells,
and incubated for 2 h. After the washes, 100 µl of mouse
monoclonal anti-human factor H (OX-23, LifeSpan BioSciences),
which recognizes the SCRs 1–4 of the FH N-terminal domain,
were added at a 1:10,000 dilution in blocking solution. Notably,
this anti-human factor H antibody also detected the FH-like
1 (FHL1) which shares the N-terminal domain with FH. The
plate was washed and 100 µl of goat anti-mouse antibody
conjugated with HRP (1:2,000, Thermo Fisher) were added and
incubated for 1 h. Enzymatic activity was revealed using the
TMB substrate.
SDS-PAGE and Western Blotting
FHR1 was studied by Western blotting in the serum of all
patients with anti-FHs with at least one copy of CFHR1.
Sera were diluted 1:40 in loading buffer (4X Laemmli
Sample Buffer, Bio-Rad) in non-reducing conditions and
analyzed using sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE, Mini-Protean TGX Precast Gels,
Bio-Rad). Proteins were transferred to polyvinylidene difluoride
membrane (PVDF, Trans-Blot Turbo Midi PVDF Transfer;
Bio-Rad), and blocked with 4% skim milk and 1% BSA.
Mouse anti-human FHR1 IgGs (1:1,000, kindly given by Prof.
Peter Zipfel) (42), which recognizes the N-terminal domains
of FHR1, were added for 1 h. The binding of the antibody
was detected by 1 h incubation with HRP goat anti-mouse
IgG (1:5,000), followed by enhanced chemiluminescence (ECL)
substrate (Amersham).
Measurement of CFH and CFHRs
Copy Number
Multiplex-ligation dependent probe amplification (SALSA
MLPA P236-A3 ARMD, MCR-Holland, Netherlands) was used
to evaluate the presence of copy number variations (CNVs) in
CFH, CFHR3, CFHR1, CFHR2, CFHR5 genes in the 30 aHUS
patients with anti-FHs. The CFHR4 CNV was evaluated in aHUS
patients with anti-FHs by a multiplex PCR, as reported by Moore
et al. (22). To evaluate the presence of the homozygous deletion
of CFHR1 in all 305 aHUS patients, and in the 960 healthy adult
controls a multiplex PCR was set up that amplifies a 133 bp
fragment in intron 3 of CFHR1 and a 83 bp fragment in the
promoter of RNAseP.
Primers: CFHR1-For 5′-ATCACTACACATGGACCTGAAA-
3′;CFHR1-Rev 5′-GATGTGGAAAAATAAAAGAAAATAAGTC-
3′; RNAseP-For 5′-TAGATACCGTGTGCGTGCAT-3′; RNaseP-
Rev 5′-GGGGTTCCAATTCCCAACTA-3′.
Genetic Screening
Through next-generation sequencing we performed genetic
screening of all exons and flanking regions of CFH, CD46,
CFI, CFB, C3, and THBD by highly multiplex PCR using the
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Ion AmpliSeqTM Library Kit on an Ion PGM Sequencer (Life
Technologies) (34).
LPVs were defined as genetic variants with Minor Allelic
Frequency (MAF) in the ExAC database≤0.001 and a Combined
Annotation Dependent Depletion (CADD) pathogenic score
≥20 (43). Considering the complexity of aHUS and the very low
penetrance we also considered as likely pathogenic, variants with
aMAF≤0.01 for which there was evidence of functional effects in
literature. In addition, we included as likely pathogenic, genetic
variants with MAF ≤0.01 for which an association with aHUS
was reported (P-value <0.001, vs. “ExAC all” in the database of
complement gene variants, www.complement-DB.org).
The CFH promoter and the coding and flanking regions of
CFHR1 were analyzed by direct sequencing.
Statistical Analyses
All statistical tests were executed using MedCalc software.
The Chi-square test or the Fisher’s exact test were used
to compare the allele frequencies between cases and
“supercontrols,” as appropriate. The expectation maximization
algorithm by Haploview software was used to estimate
each CFH haplotype frequency. Findings were considered
statistically significant at P-values <0.05 after Bonferroni
correction. Odds ratio (OR) was reported with the 95%
confidence interval. ANOVA or Kruskal-Wallis tests were
used to compare the mean or the median of variables,
as appropriate.
RESULTS
Factor H Autoantibodies
The presence of anti-FHs was assessed in 305 consecutive aHUS
patients of the International Registry of HUS for whom serum
or plasma was available. Thirty patients (9.8%) were positive
for anti-FHs (anti-FHs titer threshold >56 AU/ml); in all of
them the specificity of the result was confirmed in a replicated
assay, in which an excess of FH was added to the serum/plasma
sample and competed for the anti-FHs with FH coated on the
well (Figure 1). The mean ± SD of anti-FH titers was 1,164.7 ±
1,189.5 AU/ml in samples collected during the acute phase of the
disease (n = 4) and 521.8 ± 504.3 AU/ml in samples collected
during remission (n= 26; ANOVA, P-value= 0.062).
FHR1 Deficiency
In all 30 patients with anti-FHs aHUS, copy numbers were
evaluated by MLPA for CFH, CFHR3, CFHR1, CFHR2, and
CFHR5 and by a multiplex PCR for CFHR4. The homozygous
CFHR3-CFHR1 deletion was observed in 20 patients (66.7%) and
the heterozygous CFHR3-CFHR1 deletion combined with the
heterozygous CFHR1-CFHR4 deletion was present in 4 patients
(13.3%, Table 1). Overall, 24 patients had zero copies of CFHR1
(80%, Table 1). Four patients showed the heterozygous deletion
of CFHR3 and CFHR1 (13.3%) and in two patients no CNV in
CFHR genes were identified (6.7%, Table 1).
Direct sequencing of CFHR1 was performed in the 6 patients
with anti-FHs and at least one copy of CFHR1. In patient 23, who
FIGURE 1 | Anti-FHs in aHUS patients and healthy controls. 305 aHUS patients were analyzed for anti-FHs through ELISA: 254 were carriers of 1 or 2 copies of
CFHR1 (aHUS with CFHR1), and 51 had 0 copies of CFHR1 (aHUS with HomCFHR1Del). Patient 23, carrying the heterozygous CFHR1Del and a frameshift variant in
CFHR1 exon 2 (c.104delAfsX), which resulted in a complete deficiency of FHR1 has been also included in the group of patients defined as “aHUS with
HomCFHR1Del.” Ninety-eight healthy controls with 1 or 2 copies of CFHR1 were also analyzed for anti-FHs (CTR). The positive threshold was set at mean +2SD of
values recorded in the 98 controls (56 AU/mL) and is shown with the horizontal red dashed line.
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TABLE 1 | Copy numbers of CFHR3, CFHR1, and CFHR4 and LPVs in complement genes observed in aHUS patients with anti-FHs.
Patient ID Number of copies LPVs MAF (ExAC) CADD Functional effect Association with
aHUS
(complement-db.org)CFHR3 CFHR1 CFHR4
1 0 0 2 nd
2 0 0 2 CFH c.2850G>T, p.Gln950His 0.004 21.4 Yes No
3 0 0 2 nd
4 1 0 1 nd
5 0 0 2 nd
6 0 0 2 C3 c.1909G>C, p.Gly637Arg 0.0002 23.5 No No
7 0 0 2 THBD c.1693 G>T, p.Asp486Tyr 0.006 6.12 Yes No
8 0 0 2 nd
9 0 0 2 nd
10 0 0 2 nd
11 0 0 2 nd
12 0 0 2 nd
13 1 1 2 CD46 c.762delT, p.Leu254fsX43 na 17.57 Yes No
14 0 0 2 nd
15 0 0 2 nd
16 1 0 1 nd
17 0 0 2 nd
18 0 0 2 nd
19 1 1 2 THBD c.1502C>T, p.Pro501Leu 0.002 24.7 Yes Yes
20 0 0 2 nd
21 2 2 2 C3 c.1774C>T, p.Arg592Trp 8 × 10−6 34 Yes Yes
22 0 0 2 nd
23 1 1* 2 nd
24 0 0 2 CFH c.2758T>C, p.Trp920Arg na 27 No Yes
25 0 0 2 nd
26 1 1 2 nd
27 0 0 2 CFH c.2776T>C, p.Cys926Arg na 28.4 No No
28 1 0 1 nd
29 1 0 1 THBD c. 241G>A, p.Val81Ile 9 × 10−6 8.28 Yes Yes
30 2 2 2 nd
The Minor Allelic Frequency (MAF) of LPVs from the ExAC database, the Combined Annotation Dependent Depletion (CADD) score, the availability of published data on functional effects,
and the association with aHUS in the database of complement gene variants (complement-db.org) are also shown. Nd, not detected; na, not available. *The CFHR1c.104delAfsX,
p.D35fsX36 was observed in this patient.
carried the heterozygous CFHR1 deletion, a frameshift variant
in CFHR1 exon 2 (c.104delAfsX) that resulted in a premature
stop codon (p.D35fsX36) was observed. In all six patients,
the presence of FHR1 in serum was verified by Western blot
(Figure 2). The normal pattern of two FHR1 bands was observed
in patients 13, 19, and 26 (all with one copy of CFHR1) and
patients 21 and 30 (both with two copies of CFHR1). At variance,
patient 23, who had one copy of CFHR1 plus the c.104delAfsX
frameshift mutation did not have any FHR1 band, confirming
that the mutation resulted in a non-secreted truncated protein, as
expected. Thus, in our cohort, 25/30 (83.3%) patients with anti-
FHs showed a complete deficiency of FHR1 and are defined as
cases here.
We also evaluated the prevalence of the acidic and basic FHR1
isoforms in patients with anti-FHs and with at least one copy
of CFHR1. In the basic FHR1 isoform that has been associated
with the risk of aHUS (21), the amino acids 157His, 159Leu,
and 175Glu are replaced by 157Tyr, 159Val, and 175Gln, which
make the SCR3 of FHR1 identical to the SCR18 of FH. In patients
with the heterozygousCFHR3-CFHR1 deletion, one exhibited the
basic isoform and two the acidic isoform. Both patients with two
copies of CFHR3 and CFHR1 were compound heterozygous for
the two FHR1 isoforms. Thus, we did not find an enrichment of
a specific FHR1 isoform in our aHUS patients with anti-FHs.
Amultiplex PCRwas used to identify subjects with theCFHR1
homozygous deletion in all 305 unrelated aHUS patients analyzed
for anti-FHs and in a large cohort of healthy subjects (n = 960).
Overall, 49 aHUS patients (16%) and 48 healthy subjects (5%)
were found to be homozygous for the CFHR1 deletion (OR
[95%CI] = 3.6 [2.4–5.5], P-value = 5.5 × 10−10, Table 2).
The association of the homozygous CFHR1 deletion with aHUS
strongly increased in the subgroup of patients with anti-FHs vs.
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FIGURE 2 | Detection of FHR1 by Western blotting in aHUS patients with
anti-FHs and at least one copy of CFHR1. ID numbers 13, 19 and 26: patients
with 1 copy of CFHR1; ID numbers 21 and 30: patients with 2 copies of
CFHR1; ID number 23: patient with 1 copy of CFHR1 and a frameshift
mutation in exon 2 (c.104delAfsX); ID number 12: patient with 0 copies of
CFHR1; CTR: an healthy control with two copies of CFHR1.
TABLE 2 | Prevalence of homozygous CFHR1 deletion in aHUS patients (n = 305)
and healthy controls (n = 960).
HomCFHR11 No
HomCFHR11
OR [95%CI] P-value
aHUS (n = 305) 49 (16%) 256 (84%) 3.6 [2.4–5.5] 5.5 × 10−10
Controls (n = 960) 48 (5%) 912 (95%)
aHUS anti-FH
positive (n = 30)
24 (80%) 6 (20%) 76
[29.7–194.6]
3 × 10−52
Controls (n = 960) 48 (5%) 912 (95%)
healthy controls (OR [95%CI] = 76 [29.7–194.6], P-value = 3 ×
10−52, Table 2).
Binding of Anti-FHs to FH Fragments and
Effect of Patient Sera on C5b-9 Deposition
on HMEC-1
To discern which FH epitopes were recognized by anti-FHs, anti-
FH ELISA was repeated using wells coated with N-terminal FH
(SCRs 1–5) and C-terminal FH (SCRs 15–20) fragments (kindly
given by Prof. Peter Zipfel). The results of samples from five
patients with 1 or 2 copies of CFHR1 (patients 19, 13, 30, 21, and
26) and from seven patients carrying the homozygous CFHR1
deletion (patients 16, 14, 15, 10, 25, 18, and 8) are shown in
Figure 3. Antibodies from patients 13, 19, and 30 (with 1, 1
and 2 copies of CFHR1, respectively) and from patients 8, 10,
14, 15, and 16 (with 0 copies of CFHR1) strongly bound to C-
terminus but not to N-terminus of FH. In patient 25 with the
homozygous deletion of CFHR1, we observed a less intense but
selective binding to FH C-terminal fragment. Antibodies from
patients 18 (with the homozygous deletion of CFHR1) and 21
(with two copies of CFHR1) bound weakly to both FH SCRs 1–5
and FH SCRs 15–20 and finally, antibodies from patient 26 (with
one copy of CFHR1) did not specifically bind any FH fragments.
It is possible that autoantibodies from patient 26 recognize either
central FH epitopes or epitopes exposed only in the native, full
length FH, as previously reported for other aHUS patients (22).
An ex-vivo test to evaluate complement activation at the
endothelial cell level showed that serum from two patients
(ID: 18 and 20, without LPVs and with homozygous CFHR1
deletion) taken after aHUS remission induced higher than
normal (>149%) C5b-9 deposits on cultured ADP-activated
human microvascular endothelial cells (Figure 4).
Complement Likely Pathogenic
Variants (LPVs)
CFH, CD46, CFI, CFB, C3, and THBD were sequenced in all
patients with anti-FHs and 9 were found to be carriers of LPVs
as defined in methods (30%, Table 1).
Of the 25 patients with anti-FHs and the FHR1 deficiency
(cases), 6 had LPVs (24%, Table 1). Three cases carried LPVs
in CFH (12%). Two Italian cases showed the heterozygous
CFH LPV c.2850G>T, p.Gln950His in SCR16 (rs149474608,
MAF (ExAC) = 0.004, CADD = 21.4) and the c.2758T>C,
p.Trp920Arg (CADD = 27) in SCR15, respectively. These
two patients had been previously reported by our group (3).
Moreover, the p.Gln950His variant was previously described in
another aHUS patient with anti-FHs (22), in other aHUS patients
without anti-FHs (44–46), and in a patient who had developed
TMA after renal transplantation (47). The third case was a
Jewish patient who showed the heterozygous CFH c.2776C>T,
p.Cys926Arg (CADD = 28.4) in SCR15. This variant is not
present in public databases and has not been described in aHUS
patients before. Notably, nuclear magnetic resonance studies (48)
showed that the 3 LPVs involve amino acids that located close to
each other in the three-dimensional structure of SCRs 15 and 16
of FH (Figure 5).
In an Italian case we found the C3 heterozygous
c.1909G>C, p.Gly637Arg (rs149850773, MAF (ExAC)= 0.0002,
CADD = 23.5), which is located in the Linker domain of
the C3 molecule and has not been reported in patients with
aHUS before.
We identified two THBD heterozygous LPVs: the c.1693G>T,
p.Asp486Tyr (rs41348347, MAF (ExAC)= 0.006, CADD= 6.12)
was identified in an Italian case and the c.241G>A, p.Val81Ile
(rs772288987, MAF (ExAC) = 9 × 10−6, CADD = 8.28) was
found in a case from Yemen. Both THBD variants have already
been reported in patients with aHUS (3, 49).
Of the 48 adult healthy “supercontrols” with the homozygous
deletion of CFHR1, only one carried a LPV, namely the
heterozygous CFI c.949 G>A, p.Arg317Trp [rs121964917, MAF
(ExAC) = 9.9 × 10−5, CADD = 16.27]. The FI 317Trp variant
has previously been reported to have 30% C3b and C4b cofactor
activity compared to wild type FI, but conflicting results have
been found by other authors (50, 51).
Overall, in cases the prevalence of LPVs was significantly
higher than in “supercontrols” (24 vs. 2.1%, Fisher’s exact test,
P-value= 0.005).
Common Complement Susceptibility
Variants
We then investigated whether common genetic variants in CFH
contribute to determining susceptibility to anti-FHs mediated
aHUS by comparing the prevalence of CFH c.1-332C>T
(rs3753394), c.184G>A p.Val62Ile (rs800292), c.1204T>C
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FIGURE 3 | Binding site localization of anti-FHs detected in aHUS patients. Anti-FH binding to FH N-terminal fragment (SCRs 1–5) and FH C-terminal fragment (SCRs
15–20) evaluated in 12 aHUS patients. Seven patients were carriers of the homozygous CFHR1 deletion (HomCFHR11) while 5 patients presented at least one copy
of CFHR1 (No HomCFHR11). BSA coating was used as negative control and full length FH coating as positive control. Absorbance of serum from a healthy subject
was used as an additional control. The absorbance is shown on the ordinate axis. Data are representative of three experiments.
FIGURE 4 | Complement activation on endothelial cells. Endothelial surface area covered by C5b-9 staining after incubation of ADP-activated HMEC-1 with serum
from aHUS patients with anti-FHs studied at remission (patients 18 and 20). For each sample, values were expressed as the percentage of C5b-9 deposits induced
by a pool of sera from 10 healthy controls run in parallel (reference 100%). The red dashed lines indicated the normal range (60–149%) determined by testing single
sera from 35 different healthy controls.
p.Tyr402His (rs1061170), c.2016A>G Gln572Gln (rs3753396),
c.2237-543G>A (rs1410996), c.2808G>T Glu936Asp
(rs1065489) in the 25 cases and in the 48 “supercontrols.”
As shown in Table 3, allele frequencies did not differ between
cases and “supercontrols.”
CFH haplotypes were also studied in cases and
“supercontrols.” The minimal informative SNPs within the CFH
gene considered for this analysis were rs3753394 (promoter),
rs800292 (exon 2), rs1061170 (exon 9), rs3753396 (exon 14),
rs1410996 (intron 15), and rs1065489 (exon 19). The most
frequent CFH haplotype was the CGTAAG (H4a haplotype),
with a frequency of 0.492 in cases and 0.638 in “supercontrols,”
followed by the TGTAAG (H4b haplotype, Table 4), with no
difference between cases (0.338) and “supercontrols” (0.279).
On the contrary, the frequency of the H3 CFH haplotype
(TGTGGT), which had previously been associated with aHUS
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FIGURE 5 | 3D structure by nuclear magnetic resonance of SCR15 and SCR16 of FH (PDB code: 1HFH). Black arrows indicate the FH amino acid residues Trp920,
Cys926 (SCR15), and Gln950 (SCR16) (colored in black) which are substituted in three aHUS patients with anti-FHs due to the Trp920Arg, Cys926Arg, and Gln950His
heterozygous mutations. Each amino acid is represented with a specific color. The first amino acid of SCR15 (Glu866) and the last amino acid of SCR16 (Ile985) are
also indicated. Cysteine residues are shown in yellow color. Created by Jmol, an open-source Java viewer for chemical structures in 3D (http://www.jmol.org).
(15) was very low and estimated to be 0.024 in cases and 0.01
in “supercontrols” (P-value = 0.04, Table 4). Notably, the
frequency of the CFH H3 haplotype in aHUS patients without
anti-FHs of our cohort (n= 275) was 0.292 and was significantly
higher compared to cases (P-value = 0.0002), “supercontrols”
(P-value = 5.6 × 10−8) as well as the general population (H3
haplotype frequency = 0.203, among 2,504 controls from 1,000
genomes project, P-value= 1.85× 10−6).
In summary, no significant association has been found
between CFH haplotypes and anti-FHs mediated aHUS, using
“supercontrols” as the reference group.
In our cohort of aHUS patients with anti-FHs, the H4a and
H4b CFH haplotypes were in strong LD with the CFHR3-CFHR1
deletion (Table 5), which is consistent with published data (16),
while the H5 andH3 haplotypes were associated with theCFHR1-
CFHR4 deletion (Table 5).
The frequency of the CD46 c.∗783C allele (rs7144) that tags
the CD46GGAAC aHUS risk haplotype (52), did not differ between
cases (0.38) and “supercontrols” (0.35, Table 3). On the contrary,
the frequency of the C allele was significantly higher in our aHUS
patients without anti-FHs (0.45) as compared with the 2,504
controls (allele frequency: 0.35) from the 1,000 genomes project
(P-value= 0.001).
Moreover, we studied the prevalence of common
polymorphisms in C3 c.941C>T, p.Pro314Leu (rs1047286), C3
c.304C>G, p.Arg102Gly (rs2230199), CFB c.94C>T, p.Arg32Trp
(rs12614), CFB c.95G>A, p.Arg32Gln (rs641153) and THBD
c.1418C>T, p.Ala473Val (rs1042579), which were previously
reported in association with other immune-mediated diseases,
including C3 glomerulopathy (33, 34), IgA nephropathy (35),
and age-related macular degeneration (36–38). No significant
difference was found with regard to allele frequencies of any
of the above single nucleotide polymorphisms (SNPs) between
cases and “supercontrols” (Table 3).
Finally, we analyzed the combination of the three variants FH
Val62, FB Arg32, and C3 102Gly, which in functional studies (53,
54) have been associated with higher C3 convertase activity (risk
complotype), and we did not find any difference in the prevalence
of the risk complotype between cases (0.24) and “supercontrols”
(0.17, P-value= 0.39).
Genetic Screening of CFH Promoter
We then wondered whether rare variants in the CFH promoter
that could affect FH expression in the thymus may predispose
to a lack of central tolerance toward FH and to the development
of anti-FHs HUS. The analysis through Matinspector software
(Genomatix) revealed the presence of two sequences predicted
with a good score as consensus motifs for the “autoimmune
regulator” transcription factor (AIRE, Figure 6), a DNA binding
molecule that is involved in central thymic tolerance by
promoting the expression of tissue-specific antigens in medullary
thymic epithelial cells. We sequenced the c.1-1070 region
upstream the CFH gene, including the two predicted AIRE
consensus regions, in our aHUS patients with anti-FHs.
We did not find any rare variant (with MAF≤0.01) in the two
DNA sequences predicted as AIRE consensus regions or in the
entire sequenced CFH promoter region.
Clinical and Biochemical Features at
Disease Onset
Clinical and biochemical features at onset for all the 30 patients
with anti-FHs are reported in Table 6.
The large majority of patients with anti-FHs in our cohort
were Caucasian (53% males, Table 6). All but one developed
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TABLE 3 | Prevalence of common variants in CFH, CD46, CFB, C3, and THBD in
cases (n = 25) and “supercontrols” (n = 48).
Genotype Sum Allele frequencies P-value
Hom WT Het Hom Var WT Var
CFH c.1-332C>T (rs3753394)
Cases 7 13 5 25 0.54 0.46 ns
Supercontrols 19 26 3 48 0.67 0.33
CFH c.184G>A Val62Ile (rs800292)
Cases 20 5 0 25 0.90 0.10 ns
Supercontrols 42 6 0 48 0.94 0.06
CFH c.1204T>C Tyr402His (rs1061170)
Cases 22 2 0 24 0.96 0.04 ns
Supercontrols 47 1 0 48 0.99 0.01
CFH c.2016A>G Gln572Gln (rs3753396)
Cases 22 3 0 25 0.94 0.06 ns
Supercontrols 46 2 0 48 0.98 0.02
CFH c.2237-543G>A (rs1410996)
Cases 0 4 21 25 0.08 0.92 ns
Supercontrols 0 2 46 48 0.02 0.98
CFH c.2808G>T Glu936Asp (rs1065489)
Cases 22 3 0 25 0.94 0.06 ns
Supercontrols 47 1 0 48 0.99 0.01
CD46 c.*783T>C (rs7144)
Cases 10 11 4 25 0.62 0.38 ns
Supercontrols 19 24 5 48 0.65 0.35
CFB Arg32Trp/Gln (rs12614, rs641153)
Cases 15 9 1 25 0.78 0.22 ns
Supercontrols 33 15 0 48 0.84 0.16
C3 c.941C>T Pro314Leu (rs1047286)
Cases 17 8 0 25 0.84 0.16 ns
Supercontrols 33 13 2 48 0.82 0.18
C3 c.304C>G Arg102Gly (rs2230199)
Cases 14 11 0 25 0.78 0.22 ns
Supercontrols 33 13 2 48 0.82 0.18
THBD c.1418C>T Ala473Val (rs1042579)
Cases 16 9 0 25 0.82 0.18 ns
Supercontrols 37 11 0 48 0.89 0.11
Hom, homozygous; WT, wild type; Het, heterozygous; Var, variant; ns, not significant. For
the CFB Arg32Trp/Gln triallelic SNP “var” includes both Trp and Gln variants. Cases: aHUS
patients with anti-FHs and FHR1 deficiency; “supercontrols”: adult healthy subjects with
homozygous CFHR1 deletion.
aHUS during childhood or adolescence (96.7%). The median age
of disease onset was 7.6 [6.6–9.9] years (Table 6). The outliers
were a woman who developed anti-FHs aHUS at 30 years of age
after a cesarean delivery and a child who manifested aHUS at
16 months (he also carried a THBD LPV). The distribution of
the age at disease onset in patients with anti-FHs was unimodal,
with a sharp incidence peak around 8 years of age (Figure 7A),
which was significantly different from aHUS patients negative
for anti-FHs who exhibited a bimodal distribution, with an early
peak before 4 years of age, and a late peak during adulthood
(Figure 7B). Similar bimodal distribution was observed when
we considered only patients negative for anti-FHs and carrying
TABLE 4 | Estimated CFH haplotypes in the 25 cases and the 48 “supercontrols.”
Estimated CFH
haplotype
Haplotype reference
number
Haplotype frequency P-value
Cases Supercontrols
CGTAAG H4a 0.492 0.638 ns
TGTAAG H4b 0.338 0.279 ns
CATAAG H2 0.07 0.019 ns
TGCAGG H5 0.042 0 ns
TGTGGT H3 0.024 0.01 0.04
The estimated allele frequencies of each CFH haplotype in cases (aHUS patients
with anti-FHs and FHR1 deficiency) and “supercontrols” (adult healthy subjects with
homozygous CFHR1 deletion) were shown. The minimal informative SNPs within CFH
gene considered for this analysis were rs3753394, rs800292, rs1061170, rs3753396,
rs1410996, and rs1065489.
TABLE 5 | Linkage disequilibrium between CFH haplotypes and CFHR3-CFHR1
or CFHR1-CFHR4 deletions in the 30 aHUS patients with anti-FHs.
Estimated
CFH
haplotype
Haplotype
reference
number
CFHR3-
CFHR1
deletion
CFHR1-
CFHR4
deletion
Frequency
mean
CGTAAG H4a Yes No 0.504
TGTAAG H4b Yes No 0.329
CATAAG H2 Yes No 0.059
TGCAGG H5 No Yes 0.042
TGTGGT H3 No Yes 0.021
Yes, deleted allele; No, normal allele. The last right column shows the estimated
frequencies of the extended haplotypes including CFH and the CFHR3-CFHR1-
CFHR4 region.
complement gene abnormalities (in CFH,MCP, CFI, THBD, C3,
and CFB; Figure 7C).
Through logistic regression we estimated that the
homozygous deletion of CFHR1 and age at disease onset
between 4 and 12 years were strongly associated with the risk
for an aHUS patient to present anti-FHs. Twenty-four out of
30 aHUS patients with anti-FHs (80%) vs. 25 out of 275 aHUS
patients without anti-FHs (9%) had the homozygous deletion
of CFHR1 (OR [95% CI] = 40 [14.9–107.1], P-value = 1.4 ×
10−22, Table 7). Twenty-four out of 30 aHUS patients with
anti-FHs (80%) vs. 27 out of 275 aHUS patients without anti-FHs
(9.8%) developed the disease between 4 and 12 years of age (OR
[95% CI] = 37 [13.8–97.9], P-value = 1.7 × 10−21, Table 7).
The combination of the homozygous CFHR1 deletion and age
at disease onset between 4 and 12 years further increased the
risk to have anti-FHs aHUS (OR [95% CI] = 108 [33.7–346.5],
P-value= 6.9× 10−33, Table 7).
Prodromal signs were observed in most (70%) anti-FH
positive patients: twelve patients (40%) exhibited gastrointestinal
symptoms (four of them with fever), and nine patients (30%) had
upper respiratory tract infections (including flu like symptoms).
One patient developed aHUS post-partum and another while on
oral contraception. Five patients did not have any prodromal
signs or triggers and for two patients trigger data were not
available (Table 6). At disease onset, all patients showed anemia,
thrombocytopenia, high LDH levels, and high serum creatinine.
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FIGURE 6 | CFH promoter sequence. Exon 1 (yellow), basal promoter (light gray), proximal promoter (dark gray), and two AIRE consensus sequences predicted by
Matinspector software–Genomatix (underlined) are shown.
Twenty-three (77%) patients developed kidney failure requiring
dialysis (Table 6).
Among patients with anti-FHs, we did not find any significant
difference in the age of onset and in clinical complement
parameters between cases with FHR1 deficiency and patients with
one or two copies of CFHR1 (Table 6), as well as between patients
with or without LPVs (Table 6).
Complement Profile
Data on serum C3 and C4 levels at the time of anti-FH antibody
assay were available for 28 patients (Table 8). Fourteen patients
(46.7%) had lower than normal serum C3 levels, in most of
them C3 was measured during convalescence (Table 8). C4
levels, on the contrary, were normal in all patients (Table 8).
Plasma FH plus FHL1 levels were in the normal range in all
patients (Table 8) with the only exception being patient 14
(studied in remission and with a high antibody titer, 1,557.3
AU/ml) who had 80 mg/l FH (Table 8). Plasma FH plus
FHL1 levels did not differ between patients studied during
the acute episode and patients studied in remission (acute:
340.3 ± 49.3 mg/l n = 3; vs. remission: 344.7 ± 117.1 mg/l,
n = 21; ANOVA, P-value = 0.951) and did not correlate with
the antibody titer (r2 = 0.0085, P-value = ns). The latter
finding would indicate that the antibodies used in our FH
ELISA assay were detecting total FH, including free FH and
immune-complexed FH (55), which is consistent with previously
published studies (17, 56).
Clinical Outcome
During amedian of 36months follow-up (IQR= 12–72months),
11 patients with anti-FHs experienced relapses of the disease
(37%): 9 had the FHR1 deficiency, one the FHR1 deficiency plus
a LPV in CFH and one a LPV in CD46 and 1 copy of CFHR1.
Overall, 15 patients (50%) developed end stage renal disease
(ESRD): 8 had the FHR1 deficiency, 2 the FHR1 deficiency
plus a LPV in C3 and CFH, respectively and 2 a LPV in THBD
(and 1 copy of CFHR1) and C3 (and 2 copies of CFHR1),
respectively. The prevalence of relapses or ESRD during the
follow-up did not differ statistically between patients with or
without LPVs (relapses: patients with LPVs 22%, without LPVs
43%; P-value = 0.42, ESRD: patients with LPVs 44%, without
LPVs 52%; P-value= 1.0).
Four patients received kidney transplantation and aHUS
recurrence was observed in one of them, who also carried the C3
heterozygous LPV p.Arg592Trp. Another patient died following
the transplant due to clinical complications unrelated to aHUS.
DISCUSSION
Here we report the results of a retrospective study in a large
cohort of patients with aHUS in which we described the clinical
and genetic features of 30 patients with anti-FHs.
Through combined CNV analysis and CFHR1 sequencing we
confirm that the FHR1 deficiency is strongly associated with
anti-FHs aHUS. Moreover, through an approach based on the
inclusion of “supercontrols,” we demonstrate that patients with
anti-FHs are enriched in complement gene LPVs, while common
complement gene variants known to increase the risk of aHUS or
other immune -mediated diseases do not significantly contribute
to anti-FHs aHUS.
The prevalence of anti-FHs in our cohort of aHUS patients
(10%) is consistent with data from other European cohorts (5–
13%) (28), but is lower than that observed in an Indian aHUS
cohort in which the percentage of anti-FH positive patients was
dramatically higher up to 56.1% (57).
Frontiers in Immunology | www.frontiersin.org 10 May 2019 | Volume 10 | Article 853
Valoti et al. Genetics of Anti-FH Autoantibodies-Associated aHUS
TABLE 6 | Clinical and biological data at onset of the 30 patients with anti-FH associated aHUS.
ID Sex Ethnicity Population Disease onset
Age (years) Disease
triggers
Hb
(14–18 g/dl)
LDH
(266–500 U/L)
Platelets
(150–400 ×103/ul)
Creatinine
(0.5–0.8 mg/dl)*
Dialysis
(yes/no)
1 F Caucasian (Eu) Italian 7.0 Vomiting 4.5 na 38,000 2.7 Yes
2 M Caucasian (Eu) Italian 7.7 Flu like 6.3 4,185 64,000 1.6 No
3 F Caucasian (Eu) Portuguese 7.6 Resp.
infection
8.5 538 78,000 4.9 Yes
4 F Caucasian (Eu) German 8.0 None 6 2,464 16,000 1.56 Yes
5 M Caucasian (Eu) Italian 8.8 Vomiting 6 na 167,000 9.4 Yes
6 M Caucasian (Eu) Italian 6.2 Flu like 6.9 na 30,000 6.9 Yes
7 M Caucasian (Eu) Italian 5.7 None 6.5 3,650 58,000 2.4 No
8 M Caucasian (USA) American 6.7 na na na na na Yes
9 F Caucasian (Eu) Serbian 7.6 Vomiting 10.4 5,120 48,000 7 Yes
10 F Caucasian (Eu) Serbian 6.6 Resp.
infection
6 2,022 124,000 1.25 No
11 F Caucasian (Eu) Italian 5.4 Vomiting 7 2,930 42,000 2.8 Yes
12 M Caucasian (Eu) Italian 7.8 Vomiting 6.8 2,866 96,000 1.9 Yes
13 F Caucasian (Eu) Turkish 12.8 None 10.6 1,767 12,000 2.6 No
14 F Caucasian (Eu) Bulgarian 15.5 Vomiting,
fever
9 3,597 79,000 3.7 Yes
15 M Caucasian (Eu) Polish 11.0 Vomiting 7.8 1,908 43,000 4.3 Yes
16 F Caucasian (USA) American 10.5 Vomiting,
fever
8 na 29,000 11 Yes
17 F Caucasian (USA) American 5.3 Flu like 8 1,422 120,000 3 Yes
18 M Caucasian (Eu) Italian 10.1 Vomiting 5.2 3,770 70,000 7 No
19 F Caucasian (Eu) Italian 8.8 na 7.2 na 60,000 4 Yes
20 F Caucasian (Eu) Dutch 30.2 Cesarean 9.5 3,362 40,000 1.8 No
21 F Hispanic Argentine 17.6 Oral
contraceptive
na na na na Yes
22 M Caucasian (Eu) Polish 7.6 Resp.
infection
9 na na 9 Yes
23 M Asian Japanese 9.2 Vomiting,
fever
6.5 2,569 15,000 2 Yes
24 M Jewish Israeli 5 None 4.8 1,091 76,000 1.5 Yes
25 M Persian Iranian 15.0 Resp.
infection
8 7,752 23,000 5.7 Yes
26 M Hispanic Argentine 6.5 None 9 na 18,000 3.5 Yes
27 M Caucasian (Eu) Italian 7.1 Resp.
infection
6.6 na 52,000 4.7 Yes
28 F Caucasian (Eu) Italian 8.1 Vomiting,
fever
na na na na Yes
29 M African-Arab Yemenian 1.3 Resp.
infection
5 1,916 150,000 0.6 No
30 M Caucasian (Eu) Belorussian 6.9 Vomiting 5.8 5,619 62,000 2.33 Yes
Median
[IQR]
Mean ± SD Mean ± SD Mean ± SD Mean ± SD % Yes
Overall 7.6 [6.6–9.9] 7.3 ± 1.4 3,081.5 ± 1,736 61.923 ± 41,218 5.7 ± 3.3 77
FHR1 deficiency Yes 7.6 [6.6–9.2] 7.1 ± 1.3 3,010 ± 1,696 66,272 ± 42,332 6.5 ± 3.4 76
No 8.8 [6.9–12.8] 8.2 ± 2.1 3,693.0 ± 2,723.8 38,000 ± 26,683 3.3 ± 1 80
P-value 0.4 0.23 0.61 0.21 0.4 0.7
LPVs Yes 7.1 [5.7–8.8] 5.6 ± 0.9 2,521.8 ± 1,325.0 62,750 ± 40,679 3.3 ± 1 56
No 7.8 [6.9–10.1] 7.6 ± 1.3 3,281.4 ± 1,832.7 61,555 ± 42,621 6.5 ± 3.4 86
P-value 0.32 0.34 0.42 0.95 0.38 0.18
The Patient ID, the sex (F, female; M, male), the ethnicity, the population of origin, the age at the disease onset, the observed triggers, hemoglobin (Hb), lactate dehydrogenase (LDH),
platelet count, serum creatinine and the need for dialysis are shown. na, not available. Normal values are in brackets. *Normal values for children between 5 and 10 years. For children
<1–5 years, 0.3–0.5 mg/dl; for children >10 years/adults, 0.5–1.2 mg/dl.
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Finding that 83% of our aHUS patients with anti-FHs had
a complete FHR1 deficiency due to the homozygous CFHR3-
CFHR1 deletion or, more rarely, to compound heterozygous
FIGURE 7 | Distribution of age at disease onset in aHUS patients analyzed for
anti-FHs. (A) Patients with anti-FHs (n = 30); (B) Patients without anti-FHs (n
= 275), and (C) Patients without anti-FHs and carrying LPVs in complement
genes (n = 99).
CFHR3-CFHR1 and CFHR1-CFHR4 deletions is consistent with
earlier published studies in other cohorts (21, 22). Interestingly,
we describe a FHR1-deficient patient carrying the CFHR1
deletion in one allele and a frameshift CFHR1 mutation causing
an early termination of protein translation in the other allele. To
the best of our knowledge only one other aHUS patient with anti-
FHs and a truncating CFHR1 mutation has been described in a
published study (21). However, we found 5 patients with anti-
FHs carrying at least one normal copy of CFHR1, indicating that
autoantibodies against FH can also be formed in the presence
of FHR1.
In agreement with previous reports (24–27, 58), anti-FHs
from 92% of our patients predominantly targeted the C terminus
of FH, which is a mutational hot spot in aHUS and a crucial
domain involved in the regulation of the complement AP on cell
surface (59). Our results, showing that serum from two patients
with anti-FHs and no LPVs in complement genes induced
higher than normal C5b-9 deposits on cultured endothelial cells,
support a pathogenetic role of anti-FHs in causing complement
dysregulation on endothelium (58, 60). This finding is in line
with previous studies showing that aHUS-associated anti-FH
autoantibodies impaired FH capability to protect rabbit or sheep
erythrocytes from complement-mediated lysis (25, 61).
The mechanisms that link the lack of FHR1 to the
development of anti-FHs have not been clarified yet. Evidence
that the FH C-terminal domain is homologous to FHR1 C-
terminus (62) and that most anti-FHs cross-react with SCRs 4–5
of FHR1 (22, 26) suggested that the absence of FHR1 plays a role
in the loss of tolerance to FH (28). In the CFH promoter region
we identified two sequences predicted as possible consensus site
for the binding of AIRE, a transcription factor that is crucial for
the expression of tissue-specific antigens in the thymus and the
maintenance of central tolerance (63–65). However, the failure to
find any variant in the CFH promoter in our patients with anti-
FHs aHUS does not support the hypothesis that there is a defect
of central tolerance related to AIRE in anti-FHs development.
Of relevance to understand the immunologic basis of anti-
FHs, are data that the large majority of patients with anti-
FHs of our cohort had prodromal infectious illnesses, most
commonly upper respiratory tract and gastrointestinal infections,
and developed the disease between 4 and 12 years of age, which
corresponds to the peak of incidence of common infections.
TABLE 7 | Estimate of the risk of an aHUS patient having anti-FHs in the presence of CFHR1 homozygous deletion and/or age at disease onset between 4 and 12 years.
Anti-FHs Sensitivity Specificity OR [CI 95%] P-value
Positive Negative
Hom CFHR11 Yes 24 25 0.80 0.91 40 [14.9–107.1] 1.4 × 10−22
No 6 250
Onset 4–12 years 24 27 0.80 0.90 37 [13.8–97.9] 1.7 × 10−21
Onset <4 or ≥13 years 6 248
Hom CFHR11 and onset at 4–12 years Yes 20 5 0.67 0.98 108 [33.7–346.5] 6.9 × 10−33
No 10 270
OR, odds ratio.
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TABLE 8 | Serum C3, C4, and plasma FH + FHL1 levels evaluated at the time of
anti-FH measurement.
Patient
ID
Biochemical complement parameters
Disease
phase
Anti-FH titer
(AU/mL)
C3 level
(90–180
mg/mL)
C4 level
(10–40
mg/mL)
FH+FHL1 level
(172–507 mg/L)
1 Rem 453.4 30 12 na
2 Rem 381.6 141 27 na
3 Rem 280.8 112 29 na
4 Rem 513.2 na na na
5 Rem 146.6 85 25 349
6 Rem 243.0 81 26 309
7 Rem 572.0 94 17 312
8 Rem 1,646.1 77 31 283
9 Rem 876.7 70 19 302
10 Acute 1,314.9 103 25 397
11 Acute 2,781.0 96 28 na
12 Rem 342.9 185 62 307
13 Rem 1,590.4 118 22 686
14 Rem 1,557.3 35 27 80
15 Rem 862.3 100 30 438
16 Rem 877.4 na na 308
17 Rem 189.15 106 70 446
18 Rem 531.2 75 14 463
19 Rem 226.6 78 20 374
20 Rem 111.8 149 38 432
21 Rem 96.6 39 25 244
22 Rem 102.1 89 39 362
23 Acute 123.1 54 29 307
24 Rem 77.6 126 35 226
25 Acute 440.15 95 27 317
26 Rem 141.2 96 27 362
27 Rem 65.2 65 14 246
28 Rem 57.1 99 22 372
29 Rem 303.9 68 11 na
30 Rem 1,321.7 63 31 337
Mean ± SD Mean ± SD Mean ± SD Mean ± SD
Acute
(n = 4)
1,164.8 ± 1,189.5 87 ± 22.3 27.2 ± 1.7 340.3 ± 49.3
Rem
(n = 26)
521.8 ± 504.3 90.9 ± 36.3 28 ± 14 344.7 ± 117.1
The phase of the disease when the samples were collected (Rem, remission phase; Acute,
acute phase), the anti-FH titer, and serum C3, C4 levels and plasma FH + FHL1 levels
are shown. Normal ranges are in brackets; na, not available.
These findings, together with published reports showing a
high prevalence of respiratory tract infections (19, 66), and
gastrointestinal pathogens in aHUS patients with anti-FHs
(67), would support a “two-hit” model according to which
the autoimmunity toward FH could develop as a result of an
infection in subjects with genetic predisposing background (28).
Bhattacharjee et al. (26) identified an anti-FH autoantibody
epitope cluster within SCR20, which includes amino acids
used by microbes to bind FH and evade the immune system
(68–70). The authors proposed that binding of this domain with
certain microbes induces a conformation change in FH SCR20
generating a neoepitope similar to FHR1, whichmight predispose
to the development of the autoantibodies against FH in subjects
with the FHR1 deficiency.
Anti-FHs aHUS is an ultra-rare disease with a prevalence
of about 1/1,000,000 people in Europe and the USA (1,
28) which does not fit with the ∼5% prevalence of FHR1
deficiency in European Caucasian populations (29), and with
bacterial infections that commonly occur during school-age
(67). From these observations we infer that multiple genetic
and/or environmental risk factors are required for the disease to
manifest, as reported for other autoimmune disorders (71).
Recently, as a new strategy to identify genetic variants
associated with complex traits, patients were compared with
centenarians, as supercontrols, who have evaded all the common
diseases associated with aging and are expected to be depleted
in disease predisposing genetic variants or enriched in protective
variants (72, 73). Inspired by these reports, to identify other
anti-FHs aHUS genetic determinants, here we adopted a similar
approach using as “supercontrols” adults subjects with the
homozygous CFHR1 deletion who did not get anti-FHs aHUS
despite carrying the known genetic risk factor for the disease
(i.e., FHR1 deficiency) and likely having been exposed to
common infections during childhood. We hypothesized that
the comparison of our patients with anti-FHs aHUS and
FHR1 deficiency (cases) with “supercontrols” could allow us
detecting genetic variants with clinical value at relatively small
sample size. With this approach we demonstrate that cases are
significantly enriched in CFH, THBD and C3 LPVs compared
to “supercontrols.” Other authors have screened patients with
anti-FHs aHUS for complement gene defects, but there was
no comparison with a control group and the results were
conflicting (18, 19, 21–23, 32). Our data support the hypothesis
that rare complement gene variants are involved in predisposing
to anti-FHs aHUS. CFH LPVs are the most abundant in
our cases, two of which are not reported in public control
databases and are predicted to be strongly damaging in silico.
The third CFH LPV, the p.Gln950His, was also found in 4
patients without anti-FHs of our aHUS cohort and in other
published patients (22, 44–46). The functional relevance of this
variant was documented by Mohlin and colleagues (44) who
showed that the 950His variant is less effective in inhibiting
complement-mediated sheep erythrocyte lysis than the wild type
Gln950. As for the THBD variants, both have been found to
be less effective in promoting C3b inactivation to iC3b on the
cell surface (12). Finally, the C3 p.Gly637Arg has not been
described in patients with aHUS, it is predicted to be strongly
damaging by in silico analysis but functional data are not
available. We would speculate that complement LPVs contribute
to aHUS in subjects with FHR1 deficiency by synergizing
with anti-FHs in inducing AP activation on cell surfaces.
Since complement activation products can enhance the adaptive
immune response (74), the possibility that AP dysregulation
associated with LPVs per se could favor the proliferation of
the self-reactive T cell clones and the formation of anti-FHs
is worth investigating. However, further studies are required
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to clarify the mechanisms through which LPVs predispose to
anti-FHs aHUS.
We found only one LPV in the “supercontrol” group, namely
the p.Arg317Trp in FI. This variant was previously reported
to have a lower cofactor activity compared to wild type FI
(50). However, later on Nilsson and colleagues found that
the activity of the 317Trp variant was not impaired in any
functional assay, rather this variant was more efficient than
wild type FI in C3b cleavage on the surface of endothelial
cells (51).
At variance with LPVs, common genetic variants in
complement genes predisposing to aHUS or to other immune-
mediated diseases (as C3 glomerulopathy, age-related macular
degeneration, and IgA nephropathy) (33–38) were not more
abundant in our cases compared to “supercontrols.” Specifically,
the CFH H3 haplotype, which has been strongly associated
with an increased risk of aHUS (15), was rare both in cases
and in “supercontrols,” although it was slightly more prevalent
in cases. As expected, this haplotype was enriched in our
patients without anti-FHs. These results do not surprise, because
most cases and “supercontrols” share the CFH H4 haplotypes
that are in LD with the CFHR3-CFHR1 deletion. As for the
frequency of the CD46 c.∗783C allele (rs7144) variant that
tags the CD46GGAAC haplotype, described in strong association
with aHUS (52), we did not observe any difference between
cases and “supercontrols,” whereas the frequency of this allele
was significantly enriched in our aHUS patients without anti-
FHs. Altogether our data demonstrate that the CFH H3 and
the CD46GGAAC haplotypes are risk factors for aHUS without
anti-FHs but do not contribute to development of anti-
FHs aHUS.
The marked difference we observed in the age of onset
between patients with anti-FHs and those negative for
anti-FHs further supports the hypothesis that diverse
predisposing factors underlying the two forms of the disease
are involved.
Importantly, within the entire aHUS cohort reported here
we have shown that a disease onset between ages 4 and
12, identifies the presence of anti-FHs with a specificity of
90%. Patients with the above age of onset should be screened
carefully for anti-FHs. Prompt identification of anti-FHs is
of great clinical relevance since anti-FHs can be removed
by successfully plasma exchange, which also supplements free
FH and provides FHR1, which might act as a decoy for the
antibodies (75). Patients should be followed up carefully long-
term to monitor the re-emergence of anti-FHs, since this form
of aHUS is associated with a high prevalence of relapses, as
documented by published (28) and present data. Relapses can
be prevented by maintenance therapy with immunosuppressive
agents that inhibit the further production of anti-FH antibodies
(28), but these drugs may have serious side effects particularly
in children.
In conclusion, we have confirmed in our cohort of patients,
the strong association between FHR1 deficiency and aHUS
with anti-FH autoantibodies. Through an innovative approach
based on the comparison with “supercontrols” carrying the
homozygous CFHR1 deletion, identified by screening a large
number of healthy adult subjects, we have documented that
patients with anti-FHs aHUS are enriched in complement gene
LPVs. This observation indicates that the pathogenesis of anti-
FHs aHUS is complex and multiple “hits” are required for its
clinical manifestation. We also document that the CFH H3
and the CD46GGAAC haplotypes are not associated with anti-
FHs aHUS, whereas these haplotypes are enriched in aHUS
patients without anti-FHs, which highlights the differences in
the genetic basis of the two forms of the disease. Finally,
we confirm the role of common infections as environmental
factors that contribute to the development of anti-FHs aHUS
in genetically predisposed individuals. The latter finding fits
with the sharp peak of disease onset during scholar-age.
Further studies are needed to fully elucidate the genetic
and environmental factors underlying anti-FHs aHUS and to
establish whether the combination of anti-FHs with LPVs or
other risk factors influences the course of the disease and the
response to therapies.
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